Genenta Science (NASDAQ:GNTA) Announces Earnings Results

Genenta Science (NASDAQ:GNTA) issued its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.28, FiscalAI reports.

Genenta Science Stock Up 3.9%

Shares of NASDAQ GNTA traded up $0.03 during midday trading on Wednesday, reaching $0.70. 5,830 shares of the company’s stock were exchanged, compared to its average volume of 1,057,534. Genenta Science has a 52-week low of $0.59 and a 52-week high of $10.00. The business’s fifty day moving average price is $0.92 and its two-hundred day moving average price is $1.81.

Institutional Investors Weigh In On Genenta Science

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ghisallo Capital Management LLC purchased a new position in shares of Genenta Science during the 4th quarter valued at approximately $482,000. Weiss Asset Management LP bought a new stake in shares of Genenta Science in the fourth quarter worth $480,000. Norges Bank acquired a new stake in Genenta Science in the fourth quarter valued at $337,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science in the fourth quarter valued at $328,000. Finally, SmartHarvest Portfolios LLC bought a new position in Genenta Science during the 4th quarter valued at $26,000. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research report on Friday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.